Literature DB >> 12699296

Glucocorticoid-induced osteoporosis.

Kenneth G Saag1.   

Abstract

Therapeutic use of glucocorticoids can lead to many well-known adverse events. Of all potential serious side effects, glucocorticoid-induced osteoporosis (GIOP) is one of the most devastating complications of protracted glucocorticoid therapy in rheumatoid arthritis. GIOP is the most common form of drug-induced osteoporosis. Although much has been written about the association of glucocorticoids with bone disease among patients with chronic inflammatory conditions, many issues remain unsettled. This article focuses on areas of continued controversies, including the epidemiology and pathogenesis of GIOP, specification of a "safe" dose, methods for diagnosis of GIOP, and an evidence-based approach for GIOP prevention.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12699296     DOI: 10.1016/s0889-8529(02)00064-6

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  33 in total

Review 1.  Mechanisms of glucocorticoid action in bone.

Authors:  Ernesto Canalis
Journal:  Curr Osteoporos Rep       Date:  2005-09       Impact factor: 5.096

2.  [Diagnosis and treatment of osteoporosis and rheumatoid arthritis in accordance with German guidelines. Results of a survey of patients, primary care physicians and rheumatologists].

Authors:  I Heberlein; W Demary; H Bloching; J Braun; F Buttgereit; R Dreher; C Kuhn; U Lange; A Zink; H Zeidler; H Häntzschel; H Raspe
Journal:  Z Rheumatol       Date:  2011-09       Impact factor: 1.372

3.  Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).

Authors:  Baruch D Kuppermann; Leandro Cabral Zacharias; M Cristina Kenney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

4.  Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice.

Authors:  Wei Yao; Zhiqiang Cheng; Cheryl Busse; Aaron Pham; Mary C Nakamura; Nancy E Lane
Journal:  Arthritis Rheum       Date:  2008-06

Review 5.  Hepatic osteodystrophy.

Authors:  Angelo Gatta; Alberto Verardo; Marco Di Pascoli; Sandro Giannini; Massimo Bolognesi
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

6.  Does the combination of inhaled steroids with long acting beta2 agonists decrease the risk for osteoporosis? A 1-year prospective follow-up study.

Authors:  Gulden Pasaoglu; Haydar Gok; Dilsad Mungan; Birkan Sonel; Peyman Yalcin; Zeynep Misirligil
Journal:  Rheumatol Int       Date:  2006-08-25       Impact factor: 2.631

Review 7.  The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review.

Authors:  L J Peppone; S Hebl; J Q Purnell; M E Reid; R N Rosier; K M Mustian; O G Palesh; A J Huston; M N Ling; G R Morrow
Journal:  Osteoporos Int       Date:  2009-12-04       Impact factor: 4.507

8.  Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency.

Authors:  Anne Bachelot; Zeina Chakhtoura; Dinane Samara-Boustani; Jérome Dulon; Philippe Touraine; Michel Polak
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-28

9.  Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.

Authors:  B L Langdahl; F Marin; E Shane; H Dobnig; J R Zanchetta; M Maricic; K Krohn; K See; M R Warner
Journal:  Osteoporos Int       Date:  2009-04-07       Impact factor: 4.507

Review 10.  Mortality and morbidity in adult craniopharyngioma.

Authors:  Eva Marie Erfurth; Helene Holmer; Sigridur Bara Fjalldal
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.